uniQure (NASDAQ:QURE) Given Average Rating of “Moderate Buy” by Analysts

uniQure (NASDAQ:QURE) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $38.89.

Several brokerages recently issued reports on QURE. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. Leerink Partners raised their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Stifel Nicolaus lifted their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. Finally, Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th.

uniQure Stock Performance

NASDAQ:QURE opened at $14.77 on Tuesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The firm’s fifty day simple moving average is $13.80 and its 200-day simple moving average is $10.60. The stock has a market cap of $798.72 million, a PE ratio of -2.98 and a beta of 0.36.

Insider Activity

In other news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. This trade represents a 8.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 90,830 shares of company stock valued at $961,401. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC acquired a new position in shares of uniQure in the fourth quarter worth about $38,410,000. Franklin Resources Inc. purchased a new position in uniQure during the 3rd quarter worth approximately $7,360,000. RTW Investments LP raised its stake in uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after purchasing an additional 893,625 shares during the period. Point72 Asset Management L.P. boosted its position in shares of uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after buying an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC purchased a new position in shares of uniQure during the fourth quarter valued at $13,245,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.